Piramal Pharma has embarked on its sustainability journey as the Science Based Targets initiative (SBTi) officially validated the company’s near-term greenhouse gas (GHG) emission reduction targets. This validation aligns with Piramal Pharma's core purpose of ‘Doing Well and Doing Good,’ driving its business strategies and strengthening the company’s commitment to making consistent, measurable progress toward a more sustainable future.
Piramal Pharma has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year. Piramal Pharma has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution and use of sold products 25% within the same timeframe. This makes Piramal Pharma the third global pharmaceutical company in India to receive approval from the SBTi.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: